Arabic Arabic English English French French German German

EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of updated data from its partner CStone Pharmaceuticals’ Phase 3 GEMSTONE-302 study at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer (IASLC 2021 WCLC). Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Temedica Develops new Digital Companion Brisa for People with Multiple Sclerosis in Cooperation with Roche

Next Post

Cancer Immunologist Karin Pelka Joins Gladstone Institutes

Related Posts